[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-early-stage-non-small-cell-lung-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-early-stage-non-small-cell-lung-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100631266","early-phase-1-tils-therapy-for-multiple-primary-early-stage-nsclc-100631266",false,"NCT07498439","TILs Therapy for Multiple Primary Early-Stage NSCLC","Safety Study of Tumor-Infiltrating Lymphocytes (TILs) Therapy for Multifocal Early-Stage Non-Small Cell Lung Cancer (NSCLC)","Inclusion Criteria:\n\n1. Age 18-75 years, male or female;\n2. Imaging findings showing multiple pulmonary nodules persisting after one year of follow-up, clinically diagnosed as multiple lung cancers by two associate senior or higher-level radiologists, two associate senior or higher-level thoracic surgeons, and one associate senior or higher-level oncologist, with patients refusing continued observation;\n3. Patients with a history of surgical resection and pathological diagnosis of NSCLC, who subsequently show disease progression on imaging (progression of primary lesion or new nodules) during follow-up or after targeted therapy, diagnosed as lung cancer by a multidisciplinary expert team, and who refuse surgery or other treatments;\n4. Ability to obtain a tumor sample of approximately 1-1.5 cm³ via surgery, biopsy, or bronchoscopy for preparation of autologous tumor-infiltrating lymphocytes;\n5. ECOG performance status score of 0-2;\n6. HGB ≥70 g\u002FL, transfusion-eligible;\n7. No severe hepatic, renal, cardiac, or pulmonary dysfunction, meeting the following criteria:\n\n   Creatinine ≤ 1.5 × ULN; Oxygen saturation \\> 90%; Total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN;\n8. Estimated survival \\> 5 years with complete clinical documentation.\n\nExclusion Criteria:\n\n1. Patients with pathological diagnosis of small cell lung cancer components;\n2. Suspicious lesions appearing and follow-up duration less than six months, or remission after anti-inflammatory treatment;\n3. Previous history of allogeneic organ transplantation or cytoreductive therapy including lymph node clearance;\n4. Patients currently undergoing steroid therapy;\n5. Concurrent severe or persistent infections unresponsive to effective control;\n6. Concurrent severe autoimmune disease or congenital immunodeficiency;\n7. History of severe allergic reactions to biological products (including antibiotics);\n8. Active hepatitis (quantitative hepatitis B virus DNA \\[HBV-DNA\\] above the lower limit of detection for the assay method, or positive hepatitis C antibodies \\[HCV-Ab\\] with HCV-RNA above the assay method's lower limit of detection);\n9. HIV infection or syphilis infection;\n10. Female patients who are pregnant, breastfeeding, or planning pregnancy within 12 months;\n11. Conditions deemed by the investigator to potentially increase subject risk or interfere with trial results.","ALL","18 Years","75 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","This is a single-arm study aimed at evaluating the safety of TILs therapy for multiple primary early-stage NSCLC",[27],"Primary Early-stage Non-small Cell Lung Cancer",[29,30],"TILs","NSCLC","NOT_YET_RECRUITING","2026-03-25",{"date":34,"type":35},"2026-03-27","ACTUAL",{"date":37,"type":21},"2026-03-31",{"date":39,"type":21},"2030-03-31",{"name":41,"class":42},"Tianjin Medical University General Hospital","OTHER"]